Wednesday, 28 Feb 2024

Movano Health Q1 Loss Widens

Turkey's Presidential Election Heading To Runoff

Turkey’s presidential election is heading to a likely runoff as neither of the main candidates was able to win a clear majority.

With 99.78 percent of votes counted, President Recep Tayyip Erdogan secured only 49. 25 percent of votes, which was not enough to decisively extend his nine-year rule.

His main rival, Kemal Kilicdaroglu of the Republican People’s Party, could win only 44.99 percent of votes, according to state-run Anadolu news agency.

As per ANKA news agency, his vote share is 45.05 percent.

Another candidate, Sinan Ogan, received 5.28 percent of votes.

Erdogan claimed majority against his secular rival in Sunday’s presidential election.

Kilicdaroglu welcomed a second round, scheduled for May 28, and expressed confidence of winning it.

But since Erdogan’s coalition of parties has won a parliamentary majority, it could be an advantage for the incumbent in the runoff, reports said.

The hardcore Islamist leader, who was first elected as President in 2014, has survived a coup against him in 2016.

Under Erdogan’s leadership Turkey moved closer to Russia and distanced from the United States, but his economic policies have reportedly led the NATO-member state to 44 percent inflation.

Seelos Therapeutics, Inc Q1 Loss decreases, but misses estimates

Seelos Therapeutics, Inc (SEEL) announced Loss for first quarter that decreased from the same period last year but missed the Street estimates.

The company’s earnings totaled -$13.4 million, or -$0.12 per share. This compares with -$14.0 million, or -$0.13 per share, in last year’s first quarter.

Analysts on average had expected the company to earn -$0.11 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

Seelos Therapeutics, Inc earnings at a glance (GAAP) :

-Earnings (Q1): -$13.4 Mln. vs. -$14.0 Mln. last year.
-EPS (Q1): -$0.12 vs. -$0.13 last year.
-Analyst Estimates: -$0.11
-Revenue (Q1): $0.81 Mln vs. $0.00 Mln last year.

Allergan Aesthetics Says FDA Approves SKINVIVE By JUVEDERM

Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21.

SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with results lasting through six months with optimal treatment.

SKINVIVE by JUVEDERM is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine).1 Unlike other facial injectables that enhance and augment the treatment area, SKINVIVE by JUVEDERM improves skin quality in the cheeks by smoothing the skin and increasing hydration.

SKINVIVE by JUVEDERM is a specialized, smooth, hydrating gel that flows easily into the skin and is approved for all Fitzpatrick Skin Types I-VI, lightest to darkest, addressing an important unmet need in the skin quality category.

Allergan Aesthetics anticipates that SKINVIVE by JUVEDERM will be broadly commercially available within the next six months.

PDS Biotechnology Q1 Loss Widens

PDS Biotechnology Corp. (PDSB), a clinical-stage immunotherapy company, Monday, reported a wider loss for the first quarter, particularly impacted by personnel, clinical studies, medical affairs, and manufacturing expenses. The quarterly Loss per share was wider than expected.

First quarter Loss was $9.7 million or $0.32 per share, wider than the prior year loss of $8.5 million or $0.32 per share.

On average, 7 analysts polled by Thomson Reuters expected the company to report loss of $0.31 per share for the quarter. Consensus estimates typically exclude one-time items.

Operating loss widened to $9.42 million from $8.47 million for the same period of prior year.

Friday, during the regular trading hours, shares of PDS Biotechnology closed at $6.45 down 3.80% or $0.26.

Casualties Reported In New Wave Of Missile, Drone Attacks In Ukraine

Casualties were reported in a fresh wave of missile and drone attacks carried out by Russian forces across Ukraine since Sunday night.

At least one person was killed in the port city of Odesa, while five people were injured in capital Kyiv.

Other targeted cities include Kharkiv, Kherson, and Mykolaiv.

“Around midnight, the Russian occupiers attacked Odesa Oblast with Tu-22M3 long-range bombers. A total of eight missiles were launched from the area of Cape Tarkhankut (occupied Crimea). Some of the missiles did not reach their targets,” the Ukrainian air force said in a statement.

“A guard at the warehouse where an enemy missile hit was killed. His body was found under the rubble,” the spokesman for the head of the regional military administration wrote on Telegram.

Russia launched 61 air strikes and 52 long range missiles aimed at troop positions and populated areas, according to the Ukrainian military.

Ukraine claimed that it repelled the Russian attacks and downed a most-modern hypersonic weapon.

Meanwhile, the head of the annexed eastern Ukrainian region of Donetsk announced that it exported the first grain shipment from the port of Mariupol.

Movano Health Q1 Loss Widens

Movano Inc. (MOVE), a healthcare solution provider, Monday reported a wider loss for the first quarter of 2023.

The company reported first-quarter net loss of $7.1 million compared to a loss of $6.9 million for the same period last year.

The loss per share decreased to $0.19 per share from $0.21 per share due to higher number of shares outstanding this quarter.

The company announced that they will launch Evie Ring, a device used to measure heart rate and blood oxygen saturation, in September for $269 with no subscription.

Movano Health plans to launch Evie Ring as a wellness device if it has not received the FDA’s decision by the launch date and then transition it to a medical device later on.

MOVE is currently trading at $1.2600, up $0.0300 or 2.44%, on the Nasdaq.

Related Posts